Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
FEBS Letters
|
November 14, 2006
Regulation of RKIP binding to the N-region of the Raf-1 kinase
Sungdae Park, Oliver Rath, Sandy Beach, et al.
Journal of Medicinal Chemistry
|
January 18, 2012
Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity
Fang Wang, James A D Good, Oliver Rath, et al.
Journal of Medicinal Chemistry
|
February 12, 2013
Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models
James A D Good, Fang Wang, Oliver Rath, et al.
European Journal of Medicinal Chemistry
|
July 4, 2012
Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine
Murad N Abualhasan, James A D Good, Kitiyaporn Wittayanarakul, et al.
Cancer Research
|
February 10, 2011
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β
Fahd Al-Mulla, Milad S Bitar, May Al-Maghrebi, et al.
Cellular Signalling
|
February 26, 2008
The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK
Oliver Rath, Sungdae Park, Hui-hui Tang, et al.
Molecular and Cellular Biology
|
September 18, 2013
Extracellular signal-regulated kinase regulates RhoA activation and tumor cell plasticity by inhibiting guanine exchange factor H1 activity
Anne von Thun, Christian Preisinger, Oliver Rath, et al.
Translational Oncology
|
June 9, 2016
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
Hee Kyung Kim, Sun Young Kim, Su Jin Lee, et al.
Translational Oncology
|
March 23, 2017
Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma
Jiryeon Jang, Oliver Rath, Julia Schueler, et al.
Oncotarget
|
November 6, 2015
LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
Katerina Mardilovich, Mark Baugh, Diane Crighton, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
FEBS Letters
|
November 14, 2006
Regulation of RKIP binding to the N-region of the Raf-1 kinase
Sungdae Park, Oliver Rath, Sandy Beach, et al.
Journal of Medicinal Chemistry
|
January 18, 2012
Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity
Fang Wang, James A D Good, Oliver Rath, et al.
Journal of Medicinal Chemistry
|
February 12, 2013
Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models
James A D Good, Fang Wang, Oliver Rath, et al.
European Journal of Medicinal Chemistry
|
July 4, 2012
Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine
Murad N Abualhasan, James A D Good, Kitiyaporn Wittayanarakul, et al.
Cancer Research
|
February 10, 2011
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β
Fahd Al-Mulla, Milad S Bitar, May Al-Maghrebi, et al.
Cellular Signalling
|
February 26, 2008
The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK
Oliver Rath, Sungdae Park, Hui-hui Tang, et al.
Molecular and Cellular Biology
|
September 18, 2013
Extracellular signal-regulated kinase regulates RhoA activation and tumor cell plasticity by inhibiting guanine exchange factor H1 activity
Anne von Thun, Christian Preisinger, Oliver Rath, et al.
Translational Oncology
|
June 9, 2016
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
Hee Kyung Kim, Sun Young Kim, Su Jin Lee, et al.
Translational Oncology
|
March 23, 2017
Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma
Jiryeon Jang, Oliver Rath, Julia Schueler, et al.
Oncotarget
|
November 6, 2015
LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
Katerina Mardilovich, Mark Baugh, Diane Crighton, et al.
Page
of 3